NCCN Guidelines Updates

NCCN Issues First Guideline for Immunotherapy-Related Adverse Events

Wayne Kuznar

May 2018, Vol 8, No 5 - NCCN Guidelines Updates

The National Comprehensive Cancer Network (NCCN)’s first guideline (version 1.2018) for the management of side effects from immunotherapy recognizes “a new spectrum of adverse events” in patients who are receiving immune checkpoint inhibitor therapy, said John A. Thompson, MD, Director, Phase I Clinical Trials Program, Fred Hutchinson Cancer Research Center, Seattle, WA, at the 2018 NCCN annual conference. Dr Thompson is also chair of the NCCN panel on the management of immunotherapy-related toxicity. [ Read More ]

Updated NCCN Prostate Cancer Guideline Emphasizes Risk Stratification

Wayne Kuznar

May 2018, Vol 8, No 5 - NCCN Guidelines Updates

The updated prostate cancer guideline issued by the National Comprehensive Cancer Network (NCCN) continues to support early detection efforts in well-informed, healthy men, but acknowledges that the optimal screening of high-risk patients is not completely known. The guideline also supports the use of active surveillance in men who have low-risk prostate cancer. [ Read More ]